Mtech Access certified as a NICE META tool facilitating organisation
November 21, 2023 | META Tool, Medtech, NICE, diagnostics, digital health
Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment
In summary:
- Mtech Access are now a certified NICE Medtech Early Technical Assessment (META) Tool facilitating organisation, ready to support Medtech and digital health companies with the META Tool process, and their wider evidence and launch strategies
- The META Tool was developed by NICE in collaboration with Health Innovation Manchester to help Medtech companies identify gaps in their product development and evidence generation plans
- Samantha Gillard (Director – HTA), Persefoni Ioannou (Consultant – HTA), and Calum Jones (Senior Consultant – Health Economics) all recently passed the NICE META Tool assessment
- The team are hosting a free webinar on Friday 12th January at 2.00pm to explore some of the evidence challenges facing Medtech and Digital Health innovators
Mtech Access are delighted to announce that they are now a certified NICE Medtech Early Technical Assessment (META) Tool facilitating organisation. Mtech Access’ experts, Samantha Gillard (Director – HTA), Persefoni Ioannou (Consultant – HTA), and Calum Jones (Senior Consultant – Health Economics) all recently passed the NICE META Tool assessment. As accredited facilitators, the team will support Medtech and Digital Health innovators through the META Tool process and beyond. The Mtech Access Team are one of a small number of accredited organisations able to support Medtech innovators throughout commercialisation and launch.
The META Tool was developed by NICE in collaboration with Health Innovation Manchester to help Medtech companies identify gaps in their product development and evidence generation plans. The META tool process helps Medtech companies and product developers understand the evidence requirements for NICE or other payers, and the impact of the differences between regulatory and payer frameworks. It can be used at any stage of product development to explore evidence requirements.
“We are really excited to bring this new service to Medtech, Diagnostic, and Digital Health innovators. Developing the right evidence base that resonates with payers and meets the requirements of assessment bodies like NICE is increasingly important for successful launch and commercialisation. There are so many new technologies with great potential to make a real difference in healthcare settings – it’s fantastic to offer a new service to help make this happen.”
– Samantha Gillard (Director – HTA, Mtech Access).
As a certified NICE META tool facilitating organisation, via the META Tool assessment, Mtech Access will help Medtech and Digital Health companies to identify gaps in the product’s evidence package, relevant to HTA and healthcare provider evidence requirements.
In addition to the assessment itself, Mtech Access offer a full suite of HTA and medical technology commercialisation services, including strategy through to evidence generation, economic model development, submission writing, and post-submission support. Learn more about the Mtech Access META Tool service and supporting solutions at: https://mtechaccess.co.uk/meta-tool/
About Mtech Access:
At Mtech Access, we provide strategies and solutions to help Medtech companies, as well as the wider Pharmaceutical and life sciences sector, bring interventions to market, providing more patient choice and meeting the needs of the healthcare environment. Our consultants and technical experts support Global teams and affiliates throughout the product lifecycle, from evidence generation and strategy to communication of value. The HTA specialists have collectively supported over 170 UK and Ireland HTA submissions throughout their careers.
This content was provided by Mtech Access
Company Details
Latest Content from Mtech Access
NHS primary care panel – the GP Contract and Operational Planning Guidance – Live Webinar
What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future...
The role of economic evaluation in US healthcare
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...
What role does ICER play in US market access?
The Institute for Clinical and Economic Review (ICER) is becoming an increasingly important player in US market access. As more transformative, but costly, treatments come to market, payers must continue...
Mtech Access are exhibiting at ISPOR in the US
After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...
Market access and reimbursement in Canada – changes at CADTH
What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...
Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics
Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...
Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions
Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.
The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid
Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...
How does funding flow in NHSE Regions? – Live Webinar
On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...
Digital options to enhance your local market access materials
How can a digital approach enhance local customer communication, particularly when tools are adapted from existing global materials? What are the options? How can we build in efficiencies whilst meeting...
- 1
- 2